Objective. Chronic HCV infection is associated with extra-hepatic manifestations. Recent studies have suggested an immunomodulatory role for vitamin D during HCV infection. We investigated the association between serum vitamin D status and the presence of HCV extra-hepatic manifestations. Results. Overall, 84 of 94 patients (89%) had hypovitaminosis D (430 ng/ml). Patients with vitamin D deficiency vs insufficiency vs sufficiency more frequently had systemic vasculitis (P = 0.02), in particular purpura (P = 0.006), detectable MC (P = 0.008) and low C4 serum levels (P = 0.006). Serum levels of 25(OH)D were also correlated with cryoglobulin and C4 levels and with marginal zone B cells and regulatory T cells. In multivariate analysis, the presence of MC and systemic vasculitis remained independently associated with low 25(OH)D levels.
Introduction
Besides liver complications, chronic HCV infection is frequently associated with extra-hepatic manifestations, including mixed cryoglobulinaemia (MC) with or without systemic vasculitis [1] . MC can affect up to 50% of chronic HCV patients [1] and is predominantly characterized by cold-precipitable complexes of monoclonal IgM k with RF activity [1, 2] . MC-related symptoms include arthralgia, myalgia and systemic vasculitis, with manifestations ranging from palpable purpura to more severe manifestations, such as neuropathy or glomerulonephritis. A significant proportion of monoclonal MC type II can evolve into overt B-cell non-Hodgkin lymphoma (B-NHL). The mechanisms by which HCV causes B-cell lymphoproliferative disorders remain controversial, even if the hypothesis of a chronic antigen-driven proliferation is widely admitted. Several studies have demonstrated the presence of clonal B-cell expansion in the liver and blood of HCV-infected persons [37] . The implication of cellular immunity was also demonstrated in the pathogenesis of HCV MC vasculitis, through an increase of Th1 lymphocytes in vasculitis lesions [8] and a regulatory T-cell deficiency in peripheral blood [9, 10] .
It has been suggested that vitamin D plays a critical role in the regulation of the immune system by promoting the development of regulatory T cells and decreasing pro-inflammatory cytokines such as Th1 and Th17 cytokines and B-cell differentiation [11, 12] . The beneficial role of vitamin D administration in the regulation of inflammatory response and fibrogenesis has been suggested in chronic HCV infection. Recent findings in genotype 1 HCV-monoinfected patients have shown correlations between low serum 25(OH)D levels and (i) severe liver fibrosis and (ii) low sustained virological response (SVR) rates to pegylated IFN (Peg-IFN)-based therapy [13] 25 (OH)D levels were measured. All patients were followed up by the same physician (P.C.).
Patients were considered to have HCV-related vasculitis if they had, in association with clinical manifestations of vasculitis, the following: (i) histologically proven vasculitis and/or (ii) detectable MC with at least purpura as a clinical manifestation. In patients without histologically proven vasculitis, the presence of purpura was required in association with detectable MC to consider small-vessel vasculitis based on previously defined clinical and biological criteria [14, 15] . Clinical manifestations included purpura, cutaneous ulcers, arthralgia, myalgia, peripheral neuropathy (defined by clinical and/or electrophysiological abnormalities), renal involvement (defined by haematuria, proteinuria >0.5 g/day and/or glomerulonephritis on kidney biopsy), cerebral vasculitis (defined by clinical and/or MRI abnormalities), gastrointestinal involvement (defined by clinical, endoscopic and/or imaging abnormalities) and cardiac involvement (defined by clinical, electrocardiographic, ultrasonographic and/or MRI abnormalities). All patients were negative for HBV and HIV infections. The study was approved by the institutional review board (CPP-Ile-deFrance-VI, GH Pitié -Salpê triè re), and written consent was obtained from all patients.
For each patient, clinical and biological data were recorded at baseline, i.e. the time of the initial evaluation.
Clinical data included age, gender, deterioration of the general health status (asthenia and/or weight loss 510% of initial body weight), arthralgia, myalgia and cutaneous, neurological, gastrointestinal and cardiac involvement. Laboratory evaluation included a full blood count, a serum chemistry profile, the liver enzymes, the determination of the serum C4 fraction of complement, RF and cryoglobulin. A urine analysis was also completed to screen for haematuria, and a 24-hour urine collection was performed to quantify daily excretion of protein.
Cryoglobulin levels were measured and classified as previously described [16] . Patients who were MC-positive were defined as having serum MC >0.05 g/l on at least two occasions.
Overall, clinical extra-hepatic manifestations associated with chronic HCV infection included arthralgia, myalgia and systemic vasculitis-related manifestations described earlier, whereas biological extra-hepatic manifestations included the presence of MC.
Virological and immunological serum markers, HCV antibodies and RNA were detected as previously described [17] . HCV genotyping was performed using a second-generation line probe assay (LiPA; Innogenetics, Brussels, Belgium). Liver damage assessment was evaluated in the serum using non-invasive biochemical markers, i.e. serum markers that were validated for the diagnosis of liver fibrosis [18] . The liver fibrosis is graded on a 5-point scale from 0 to 4 (Metavir scoring). The activity, which reflects the amount of inflammation (specifically, the intensity of necroinflammatory lesions), is graded on a 4-point scale from 0 to 3. The diagnosis of B-NHL was based on World Health Organization criteria [19] .
Serum 25(OH)D measurement
The serum 25(OH)D level was measured in frozen serum samples taken at the time of the initial evaluation, i.e. before treatment, by means of a radioimmunoassay after simple extraction with acetonitrile (DiaSorin, Stillwater, MN, USA), as described previously [20] . Inter-and intra-assay coefficients of variation were <7% and <5%, respectively, throughout the entire range of concentrations. The detection limit was 3 ng/ml. The measurements were done in a single laboratory, which participates in DEQAS proficiency testing and finds results that fall within 10% of the all-laboratory trimmed mean of this International Quality Assessment Scheme. Vitamin D status was classified as deficiency if serum 25(OH)D levels were 412, insufficiency if between 13 and 30 ng/ml and sufficiency if >30 ng/ml.
Flow cytometry
Peripheral blood mononuclear cells were isolated from blood samples of 38 of the 94 patients included in the first part, using FicollHypaque density gradient centrifugation. Peripheral blood mononuclear cells were washed twice in PBS containing 2% fetal calf serum and numerated before labelling. The flow cytometric analysis of lymphocyte subpopulations was performed using a panel of monoclonal antibodies conjugated to FITC, phycoerythrin (PE), PE-Texas Red (ECD), allophycocyanine and phycoerythrincyanin 7 (PE-Cy7) and directed against: CD3, CD4, CD8, CD19 and IgM (Beckman Coulter), CD25 and CD27 (BD Biosciences) and CD127 (eBiosciences, San Diego, CA, USA). Irrelevant antibodies of respective isotypes were used as negative controls. Briefly, cells were incubated with the appropriate antibodies at 4 C for 30 min, washed in PBS containing 2% fetal calf serum and then fixed in PBS containing 1% paraformaldehyde. Intranuclear forkhead box P3 (FoxP3) labelling was performed after membrane staining using the allophycocyanine anti-human FoxP3 kit (PCH101 clone; eBiosciences) according to the manufacturer's instructions. Cell acquisition and analysis by flow cytometry were performed using a Navios Cytometer (Beckman Coulter 
Results

Patient characteristics
Baseline clinical and biological characteristics and HCV virological response to therapy of the 94 patients are indicated in Table 1 
Serum 25(OH)D levels
The mean serum 25(OH)D level was 18.1 ± 9.3 ng/ml. Fifty-two (55%) patients had vitamin D insufficiency, defined as serum 25(OH)D levels between 13 and 30 ng/ ml, and 32 patients (34%) had deficiency, defined as serum 25(OH)D levels 412 ng/ml (Fig. 1A) . Serum 25(OH)D levels were similar between the different HCV genotypes. A seasonal variation of serum 25(OH)D levels was observed but did not reach significance level (14.8 ± 5.9, 18.6 ± 8.7, 22.6 ± 10.9 and 16.9 ± 10.3 ng/ml in the first, second, third and fourth trimester, respectively; P = 0.07) (Fig. 1B) .
Correlations between serum 25(OH)D levels and the presence of extra-hepatic manifestations
Among the 94 patients included, 34 patients had no MC, 12 had asymptomatic MC (including type II MC in 5 patients) and 48 had MC vasculitis (including type II MC in 43 patients). Serum 25(OH)D levels were significantly lower in patients with MC vasculitis compared with those without vasculitis: 15.9 ± 8.6, 18.0 ± 11.0 and 21.3 ± 9.0 ng/ml in patients with MC vasculitis, asymptomatic MC and without MC, respectively (P = 0.03) ( Fig. 2A) .
Patients with vitamin D deficiency vs insufficiency vs sufficiency had more frequently systemic vasculitis manifestations (69 vs 46 vs 20%, respectively; P = 0.02), in particular purpura (63 vs 37 vs 10%, respectively; P = 0.006), and tended to have more frequent arthralgia (50 vs 31 vs 20%, respectively; P = 0.11), peripheral neuropathy (56 vs 40 vs 20%, respectively; P = 0.10) and renal involvement (28 vs 12 vs 10%, respectively; P = 0.11) (Table 1, Fig. 2B ). In multivariate analysis, the presence of MC vasculitis was independently associated with low 25(OH)D levels (OR = 0.93, 95% CI 0.88, 0.99; P = 0.009), female gender (OR = 2.49, 95% CI 0.98, 6.33; P = 0.052) and genotype 2 or 3 (OR = 2.73, 95% CI 0.94, 7.89; P = 0.058), but not with liver fibrosis (OR = 0.82, 95% CI 0.51, 1.31; P = 0.41), age (OR = 1.02, 95% CI 0.98, 1.05; P = 0.30) and cold season (OR = 1.45, 95% CI 0.46, 4.52; P = 0.52).
Regarding biological data, patients with vitamin D deficiency vs insufficiency vs sufficiency had more frequent MC (84 vs 56 vs 40%, respectively; P = 0.008), type II MC (69 vs 44 vs 10%, respectively; P = 0.004), low C4 serum levels (86 vs 39 vs 20%, respectively; P = 0.006) and RF positivity (72 vs 51 vs 20%, respectively; P = 0.006). A correlation was found between serum 25(OH)D levels and C4 (r = 0.42; P < 0.0001) and cryoglobulin levels (r = À 0.26; P = 0.01) (Fig. 2C and D) . In multivariate analysis, the presence of MC was independently associated with low 
Correlations between serum 25(OH)D levels and immunological parameters
Analysis of B-cell activation markers revealed a correlation between serum 25(OH)D levels and k free light chains (r = À0.44; P < 0.0001) and serum k plus free light chains (r = À0.43; P < 0.0001) (Fig. 3A) . Analysis of peripheral B-cell subsets showed a correlation between serum 25(OH)D levels and IgM + CD27 + marginal zone B cells that were demonstrated to be expanded in HCV-related MC vasculitis (r = À0.51; P = 0.001) (Fig. 3B) . Analysis of T-cell activation marker (soluble CD137) and regulatory T cells revealed a correlation between serum 25(OH)D levels and serum soluble CD137 levels (r = À0.28; P = 0.009) and CD4 + CD25 hi CD127 -FoxP3 + regulatory T cells (r = 0.58; P = 0.0005) (Fig. 3C and D) .
Discussion
In the present study, we investigated for the first time the impact of vitamin D status on the presence of extra-hepatic manifestations of chronic HCV infection, through the association between serum 25(OH)D levels and the presence of HCV-related MC and systemic vasculitis. First, we found a high prevalence of hypovitaminosis D in our study population, as 89% of HCV-infected patients had serum 25(OH)D levels 430 ng/ml. These findings are in accordance with previous studies that reported hypovitaminosis D in 73% of genotype 1 patients from Sicilia [13] and a strong association between low serum 25(OH)D levels and histological severity of hepatic steatosis, necroinflammation and fibrosis in genotype 1 HCV-infected patients [13] www.rheumatology.oxfordjournals.org and in patients with non-alcoholic fatty liver disease [21] . Previous clinical and experimental studies have suggested that 25(OH)D and 1,25(OH)D 3 could potentially interfere with fibrogenesis. The administration of active vitamin D results in significant improvement of long-term medical conditions such as chronic kidney disease and cardiovascular disorders [22, 23] , possibly through attenuation of pro-fibrotic and pro-inflammatory pathways [24, 25] . Vitamin D has also been shown to reduce the expression of collagen and pro-fibrotic factors, leading to decreased fibrosis, suggesting vitamin D supplementation as a preventive and/or early treatment strategy for related fibrotic disorders [26] , such as severe liver fibrosis in HCV-infected patients. However, low serum 25(OH)D levels in these patients could also be the consequence of liver fibrosis, as decreased 25-hydroxylation of vitamin D in the fibrotic liver could be hypothesized.
Second, we found a strong association between serum vitamin D levels and the presence of MC and systemic vasculitis in chronic HCV infection. Because vitamin D was shown to be critical in the regulation of the immune system by promoting the development of regulatory T cells and decreasing pro-inflammatory cytokines such as Th1 and Th17 cytokines and B-cell differentiation [11, 12] , analysis of serum vitamin D status in HCV-infected patients with extra-hepatic manifestations seems particularly interesting. Indeed, the implication of marginal zone B cells [7] , Th1 lymphocytes within vasculitis lesions [8] and regulatory T-cell deficiency in peripheral blood [9, 10] was demonstrated to play a role in the pathogenesis of HCV-induced MC and systemic vasculitis. Regarding the B-cell compartment, we observed significant correlations between serum 25(OH)D levels and the B-cell activation and monoclonality marker, i.e. serum free light chains, and marginal zone B cells. Serum free light chains have been shown to be an interesting marker of MC, systemic vasculitis and B-NHL in chronic HCV infection [27] . In addition, we and others demonstrated that elevated marginal zone B cells in HCV-infected patients were associated with autoimmunity and lymphoproliferation [28, 29] . Besides the B-cell compartment, we observed correlations between serum 25(OH)D levels and the T-cell activation marker soluble CD137 [30, 31] and regulatory T cells, which play a major role in the control of autoimmunity. These findings could suggest benefits from vitamin D supplementation in HCV-infected patients with MC and systemic vasculitis, in association with conventional therapies.
Limitations of the study include its small size and observational design. Indeed, even if correlative studies provide interesting and preliminary data, interventional studies with well-designed randomized controlled trials are mandatory to confirm the favourable effects of vitamin D on such manifestations.
In conclusion, low serum 25(OH)D levels correlate with the presence of MC and systemic vasculitis in chronically HCV-infected patients. These findings suggest potential multifaceted benefits of vitamin D supplementation in HCV-infected patients with extra-hepatic manifestations. Interventional studies are needed to confirm these data.
Key messages
. Vitamin D deficiency is frequent in patients with chronic HCV infection. . Vitamin D deficiency is associated with more frequent MC and systemic vasculitis in HCV patients. . Serum levels of 25(OH)D correlate with perturbations of B-cell and T-cell homeostasis in HCV patients.
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